High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy

Endocr Relat Cancer. 2016 May;23(5):L17-23. doi: 10.1530/ERC-15-0543. Epub 2016 Mar 1.

Affiliations

¹ Service de gastro-entérologie et pancréatologieHôpital Beaujon, AP-HP, Université Paris Diderot, Clichy, France.
² Service de médecine nucléaireHôpital Beaujon, AP-HP, Université Paris Diderot, Clichy, France.
³ Département de pharmacieHôpital Beaujon, AP-HP, Université Paris Diderot, Clichy, France.
⁴ Service d'hématologieHôpital Saint Louis, AP-HP, Université Paris Diderot, Paris, France pierre.fenaux@aphp.fr.

PMID: 26932783
DOI: 10.1530/ERC-15-0543

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Agents, Alkylating / therapeutic use*
Humans
Intestinal Neoplasms / drug therapy*
Leukemia, Myeloid, Acute / etiology*
Middle Aged
Myelodysplastic Syndromes / etiology*
Neuroendocrine Tumors / drug therapy*
Octreotide / analogs & derivatives*
Octreotide / therapeutic use
Pancreatic Neoplasms / drug therapy*
Risk
Stomach Neoplasms / drug therapy*
Young Adult

Substances

177Lu-octreotate
Antineoplastic Agents, Alkylating
Octreotide

Supplementary concepts

Gastro-enteropancreatic neuroendocrine tumor